TITLE:
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)

CONDITION:
Chronic Hepatitis C

INTERVENTION:
peginterferon alfa-2b (SCH 54031)

SUMMARY:

      The objective of the study is to evaluate the safety and efficacy of PEG-Intron versus no
      treatment for the prevention of fibrosis progression in adult participants with moderate to
      severe liver fibrosis secondary to chronic hepatitis C, who failed PEG-Intron plus Rebetol
      treatment in protocol P02370 (NCT00039871).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        Inclusion Criteria:

          -  Age at entry in study P02370 (NCT00039871) 18-65 years;

          -  Nonresponder to PEG-Intron plus Rebetol in study P02370

        Exclusion Criteria:

          -  Participants who did not participate in the P02370 study.

          -  Any medical condition, including but not limited to decompensated liver disease,
             malignancy or substance abuse, that developed during the P02370 study which could
             interfere with the participant's participation in and completion of this study.
      
